AIRLINK 63.80 Increased By ▲ 1.60 (2.57%)
BOP 6.18 Decreased By ▼ -0.05 (-0.8%)
CNERGY 4.98 Decreased By ▼ -0.01 (-0.2%)
DFML 14.90 No Change ▼ 0.00 (0%)
DGKC 66.97 Decreased By ▼ -2.02 (-2.93%)
FCCL 17.30 Decreased By ▼ -0.43 (-2.43%)
FFBL 24.65 Increased By ▲ 0.05 (0.2%)
FFL 9.17 Decreased By ▼ -0.04 (-0.43%)
GGL 9.90 No Change ▼ 0.00 (0%)
HBL 109.00 Increased By ▲ 0.50 (0.46%)
HUBC 116.92 Increased By ▲ 0.42 (0.36%)
HUMNL 6.70 No Change ▼ 0.00 (0%)
KEL 4.44 Decreased By ▼ -0.02 (-0.45%)
KOSM 4.66 Decreased By ▼ -0.06 (-1.27%)
MLCF 36.17 Decreased By ▼ -0.73 (-1.98%)
OGDC 122.31 Decreased By ▼ -0.99 (-0.8%)
PAEL 22.44 No Change ▼ 0.00 (0%)
PIAA 23.89 Increased By ▲ 1.67 (7.52%)
PIBTL 5.77 Increased By ▲ 0.02 (0.35%)
PPL 110.45 Decreased By ▼ -0.45 (-0.41%)
PRL 27.64 Increased By ▲ 0.07 (0.25%)
PTC 15.25 Increased By ▲ 1.06 (7.47%)
SEARL 53.15 Decreased By ▼ -0.10 (-0.19%)
SNGP 63.49 Decreased By ▼ -0.26 (-0.41%)
SSGC 10.96 Decreased By ▼ -0.04 (-0.36%)
TELE 9.32 Increased By ▲ 0.37 (4.13%)
TPLP 10.69 Decreased By ▼ -0.04 (-0.37%)
TRG 71.25 Increased By ▲ 0.95 (1.35%)
UNITY 24.52 Increased By ▲ 0.32 (1.32%)
WTL 1.37 Increased By ▲ 0.01 (0.74%)
BR100 6,733 Increased By 34.7 (0.52%)
BR30 22,615 Decreased By -3.3 (-0.01%)
KSE100 65,325 Increased By 434.2 (0.67%)
KSE30 21,670 Increased By 134.3 (0.62%)
Business & Finance

Novartis acquires manufacturing facility to produce medicines in Pakistan

  • “This investment signifies that the regulatory reforms and competitive local landscape is being recognized as an opportunity by investors," said the Advisor.
Published October 19, 2020

Novartis, a Switzerland based Multinational has acquired a manufacturing facility to produce medicines locally.

Novartis with a multi-decade presence in Pakistan and has an expansion plan that will bring an investment of about USD 20 million, informed Advisor to Prime Minister on Trade and Investment Abdul Razak Dawood on Monday.

“This investment signifies that the regulatory reforms and competitive local landscape is being recognized as an opportunity by investors," said the Advisor.

Dawood was of the view that the latest acquisition shows the confidence of international companies to invest in the future of the Pakistani pharmaceutical industry and highlights the realization of increased ease in doing business in Pakistan.

It is pertinent to mention, that Novartis maintained strong operational performance in Q1 FY 2020, its net sales from continuing operations grew 13 percent with double digits growth in Innovative Medicines and Sandoz.

Key growth drivers include Entresto USD 569 million (+62pc), Zolgensma USD 170 million, Cosentyx USD 930 million (+19pc), Kisqali USD 161 million (+82 pc) and Piqray USD 74 million, Biopharmaceuticals grew 31pc to USD 450 million, with strong growth in Europe.

Comments

Comments are closed.